Leukes, V. N.
Hella, J.
Sabi, I.
Cossa, M.
Khosa, C.
Erkosar, B.
Mangu, C.
Siyame, E.
Mtafya, B.
Lwilla, A.
Viegas, S.
Madeira, C.
Machiana, A.
Ribeiro, J.
Garcia-Basteiro, A. L.
Riess, F.
ElĂsio, D.
Sasamalo, M.
Mhalu, G.
Denkinger, C. M.
Castro, M. D. M.
Bashir, S.
Schumacher, S. G.
Tagliani, E.
Malhotra, A.
Dowdy, D.
Schacht, C.
Buech, J.
Nguenha, D.
Ntinginya, N.
Ruhwald, M.
Penn-Nicholson, A.
Kranzer, K.
,
Funding for this research was provided by:
European and Developing Countries Clinical Trials Partnership (RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007, RIA2017S-2007)
Article History
Received: 12 September 2023
Accepted: 5 December 2023
First Online: 19 January 2024
Declarations
:
: TB-CAPT CORE trial has been approved by regulatory and ethical committees in Mozambique (National IRB approval #131/CNBS/22), Tanzania (National IRB approval #NIMR/HQ/R.8c/Vol.I/2323 and TMDA approval #BD.59/62/46/05), and Germany (UKHD S-616/2021). Protocol Version 4.0, 16 January 2023. Consent is informed and voluntary, and confidentiality of participants is maintained throughout.
: Not applicable.
: The authors declare no competing interests.